Novartis recorded record results in 2009
Pharmaceuticals and vaccines have boosted the results of Swiss laboratory in 2009. Its sales totaled $ 44.3 billion, up 7% and net profit to 8.4 billion dollars. The best performances were recorded by early vaccines and diagnostics division whose sales leapt by 38% and earnings is multiplied by almost four. Novartis last year delivered more than half of 100 million doses of vaccines against influenza A. He withdrew a turnover of one billion dollars and should garner a few hundred million euros in 2010 with these products, despite the cancellations of orders scheduled by some governments, notably France.
The laboratory also benefits performance pharmaceuticals division.Its main business with a turnover of 28.5 billion dollars, "a portfolio of developing strong products," said Daniel Vasella, CEO of Novartis. Novartis has received more than 30 permits for placing on the market in 2009 and its new drugs accounted for 18% of sales in the pharmaceuticals industry in the fourth quarter, twice that in 2008 over the same period.
In 2010, Novartis will finalize the group's integration of Ophthalmology and Alcon "keep its momentum, provides Daniel Vasella. Novartis CEO for fourteen years takes off in the direction of the Basel group.He became president in charge of strategy and gives operational direction to Joe Jimenez, a 50-year-old American joined Novartis in 2007 after a long career in the consumer market.
Vaccine orders: discussions continue
Novartis continues its negotiations with France, which wants to set aside 7 million doses of the 16 million doses of vaccine ordered from the Swiss laboratory. The discussions are difficult. "Novartis believes that vaccines already made must be delivered," said Andrin Oswald, head of vaccines and diagnostics division. This represents almost two thirds of cancellations desired by France. The balance of the assignment not met, it "must be replaced by a provision" would like the Swiss laboratory. Compensation could take, for example, as a control vaccine for the upcoming campaign against seasonal influenza …